Table I.

Characteristics of study patients

Patient	Age	Duration	NIHSS 1	MRC 1	NIHSS 2	MRC 2	CVRF	Medication	Gender	Lesion
1 = A.S.	69	35	8	2 (1)	2	4 (3)	Hypertension	Enalapril, aspirin, metoprolol	m	Left putamen/ pallidum CVA
2 = I.W.	63	37	5	3 (1)	2	3	Hypertension, hypercholestremia	Enalapril, aspirin, atorvastatin	f	Left putamen/ pallidum CVA
3 = I.Z.	56	35	3	3	1	4	Hypercholestremia, patent foramen ovale	Atorvastatin, marcumar	f	Left internal capsule CVA
4 = B.M.	49	49	8	2	2	4	Nicotine abuse	Aspirin	m	Left internal capsule CVA
5 = J.G.	59	39	4	3	2	4	Hypertension	Enalapril, aspirin	m	Left putamen/ pallidum and internal capsule CVA
6 = S.S.	47	32	5	3(2)	1	4	Patent foramen ovale	Marcumar	f	Left putamen/ pallidum and internal capsule CVA
7 = A.E.	62	42	4	3	2	4	Nicotine abuse, hypertension	Enalapril, aspirin, metoprolol	m	Left putamen/ pallidum and internal capsule CVA
8 = K.S.	66	44	6	2 (1)	2	4 (3)	Hypercholestremia, patent foramen ovale	Atorvastatin, marcumar	f	Left putamen/ pallidum and internal capsule CVA

CVA, cerebral vascular accident; Duration, time between CVA onset and fMRI; NIHSS 1, NIH stroke scale at the onset of CVA; NIHSS 2, NIH stroke scale when fMRI was perfomed; MRC 1, Medical Research Council (MRC) scale at the onset of CVA for wrist extension (and finger extension in brackets if different); MRC 2 = Medical Research Council (MRC) scale for wrist extension (and finger extension in brackets if different) when fMRI was perfomed; CVRF, cardiovascular risk factors.